Recently published results show that mifepristone, but not the vitamin treatment placebo, reduced both the mitotic age and proportion of luminal progenitor cells in the normal breast tissue of healthy women and BRCA1/2 mutation carriers (124), suggesting mifepristone may be suitable for breast cancer prevention. This evidence concerns the gene BRCA1 and breast cancer.